Biologics & Biosimilars

Biosimilars the Generic form of organic is the new popular expression in pharmaceutical industry. Biosimilars are exceptionally like authorized reference item not withstanding minor contrasts in clinically idle parts; additionally there are no clinically significant contrasts between the organic and the reference item as far as wellbeing, virtue, and strength. This track incorporates: Licensing of Biosimilars, Biomarkers direction, Patent issues, BLA petitioning for Biosimilars, Regulatory prospects of BRIC nations, a worldview of customary generics to Biosimilars, Biologics& Bio waiver endorsement for Biosimilars and different parts of Biosimilar endorsements.

  • Bio-analytics for Biosimilars
  • Extrapolation and Interchangeability
  • Legal Considerations for Biosimilars
  • Biosimilar Uptake and Market Considerations
  • Challenges and regulatory approach for biosimilars
  • Future of next generation biosimilars

Related Conference of Biologics & Biosimilars

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Biologics & Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in